Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 7/20 | 1.00 |
| ▸ | HTR5A | P47898 | 2/20 | 1.00 |
| ▸ | NCF1 | P14598 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 1.00 |
| ▸ | HTR3B | O95264 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | HTR1D | P28221 | 1/20 | 1.00 |
| ▸ | HTR1B | P28222 | 1/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | HTR3A | P46098 | 1/20 | 1.00 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 1.00 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3166780 | 1.00 | HTR6 (1.00) | HTR6HTR5ANCF1HTR2AHTR3E | |
| SCHEMBL29385724 | 1.00 | HTR6 (1.00) | HTR6HTR5ANCF1HTR2AHTR3E | |
| Hydrochloric Acid SCHEMBL27664894 | 0.98 | LMNA (1.00) | HTR6HTR5ANCF1HTR2AHTR3E | |
| Hydrochloric Acid SCHEMBL466870 | 0.98 | LMNA (1.00) | HTR6HTR5ANCF1HTR2AHTR3E | |
| Hydrochloric Acid SCHEMBL25379293 | 0.98 | LMNA (1.00) | HTR6HTR5ANCF1HTR2AHTR3E | |
| SCHEMBL7719591 | 0.93 | HTR6 (0.87) | HTR6HTR5ANCF1HTR2AHTR3E | |
| Propane SCHEMBL27410088 | 0.92 | HTR6 (0.84) | HTR6HTR5ANCF1HTR2AHTR3E | |
| SCHEMBL4765551 | 0.89 | HTR6 (0.80) | HTR6HTR5ANCF1HTR2AHTR3E | |
| SCHEMBL9643856 | 0.86 | HTR1A (0.74) | HTR6HTR5ANCF1HTR2AHTR3E | |
| Trifluoroacetic Acid SCHEMBL4528245 | 0.85 | HTR6 (0.72) | HTR6HTR5ANCF1HTR2AHTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 816 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| US-20250049748-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES INC (US) | 2025-02-13 | — | — | US | claimed |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | claimed |
| US-20240165079-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2024-05-23 | — | — | US | claimed |
| EP-4313030-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | Terran Biosciences, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2024006984-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2024-01-04 | — | — | WO | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| US-20230330063-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2023-10-19 | — | — | US | claimed |
| CN-116768826-A | Rupestonic acid amide derivative containing nitrogen heterocycle, and preparation method and application thereof | 中国科学院新疆理化技术研究所 | 2023-09-19 | — | — | CN | claimed |
| EP-1568770-A2 | Pharmaceutical use of compounds which bind to a mammalian \"trace amine\" receptor | Oregon Health & Science University (US) | 2005-08-31 | — | — | EP | claimed |
| US-20050107439-A1 | Composition and method for treating emesis | HELTON DAVID R (US) | 2005-05-19 | — | — | US | claimed |
| US-20040072187-A1 | Novel mammalian receptor genes and uses | OREGON HEALTH & SCIENCE UNIVERSITY | 2004-04-15 | — | — | US | claimed |
| WO-2002022801-A9 | MAMMALIAN RECEPTOR GENES AND USES | UNIV OREGON HEALTH & SCIENCE (US) | 2003-07-03 | — | — | WO | claimed |
| EP-1319070-A2 | MAMMALIAN RECEPTOR GENES AND USES | Oregon Health & Science University (US) | 2003-06-18 | — | — | EP | claimed |
| WO-2002022801-A2 | MAMMALIAN RECEPTOR GENES AND USES | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2002-03-21 | — | — | WO | claimed |
| EP-0875512-A2 | New naphthylpiperazine derivatives with antipsychotic activity | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (FAES) (ES) | 1998-11-04 | — | — | EP | claimed |
| CN-1197067-A | New naphthylpiperazine derivatives | ESPANOLA PROD QUIMICOS (ES) | 1998-10-28 | — | — | CN | claimed |
| WO-1997028139-A1 | NOVEL NAPHTHYLPIPERAZINES DERIVED FROM SUBSTITUTED CYCLOAZANES, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS DRUGS | PIERRE FABRE MEDICAMENT (FR) | 1997-08-07 | — | — | WO | claimed |
| US-4520024-A | Method of selectively blocking peripheral vascular serotonergic receptors | ELI LILLY AND COMPANY (US) | 1985-05-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330063-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | HTR6 8/4885HTR5A 7/4885NCF1 4673/4885 |
| US-20250049748-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | PNMT, HNMT, COMT | HTR6 35/4885HTR5A 21/4885NCF1 2273/4885 |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR2A, HTR3A | HTR6 10/4885HTR5A 4/4885NCF1 4300/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | HTR6 3/4885HTR5A 2/4885NCF1 2957/4885 |
| US-20240165079-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | HTR6 7/4885HTR5A 9/4885NCF1 4721/4885 |
| US-20050107439-A1 | Composition and method for treating emesis | VIP, HNMT, FABP2 | HTR6 164/4885HTR5A 60/4885NCF1 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.